SUBSCRIBE
SUBSCRIBE
News   FDA

Bristol-Myers Squibb Company Obtains Japan Approval For Baraclude, Treatment For Chronic Hepatitis B Patients

August 4, 2006 | 
1 min read
Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry.
FDA Approvals Asia
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Pictured: Abstract collage of Statue of Liberty, temple and money
China
Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of a yellow envelope on a blue background with a read warning symbol
GLP-1
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Duchenne muscular dystrophy
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac